SCHEMBL1025928

SCHEMBL1025928

CCOC(=O)CN(CC(=O)OCC)c1cc(C(=O)NN(C)C(=O)OC(C)(C)C)ccc1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.38
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
TP53 P04637 1/20 0.35
GLA P06280 1/20 0.35
MAPT P10636 4/20 0.34
SMN1; SMN2 Q16637 4/20 0.34
LMNA P02545 4/20 0.34
KDM4E B2RXH2 3/20 0.33
GAA P10253 2/20 0.33
PTPRC P08575 2/20 0.32
ABCB1 P08183 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
NCOR2 Q9Y618 1/20 0.32
MAPK1 P28482 1/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1025855 0.92 NPC1 (0.35) ALDH1A1NPC1RAB9ATP53GLA
SCHEMBL1029808 0.88 ALDH1A1 (0.37) ALDH1A1NPC1RAB9ATP53GLA
SCHEMBL1028023 0.88 ALDH1A1 (0.40) ALDH1A1MAPTSMN1; SMN2LMNAPTPRC
SCHEMBL1025939 0.82 ALDH1A1 (0.47) ALDH1A1LMNACA12CA1CA2
SCHEMBL1029721 0.80 ALDH1A1 (0.35) ALDH1A1NPC1RAB9ATP53GLA
SCHEMBL1027539 0.79 HDAC3 (0.33) ALDH1A1MAPTSMN1; SMN2LMNAPTPRC
SCHEMBL1027462 0.77 ALDH1A1 (0.39) ALDH1A1NPC1RAB9ATP53MAPT
SCHEMBL1027230 0.77 AHCY (0.38)
SCHEMBL1024063 0.77 ALDH1A1 (0.44) ALDH1A1NPC1RAB9ATP53GLA
SCHEMBL1027534 0.75 NPC1 (0.46) ALDH1A1NPC1RAB9ATP53GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513235-B2 Homocysteine synthase inhibitor MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-08-20 US disclosed
EP-2486925-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION Mitsubishi Tanabe Pharma Corporation (JP) 2012-08-15 EP disclosed
US-20120196824-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-08-02 US disclosed
US-20110034440-A1 HOMOCYSTEINE SYNTHASE INHIBITOR MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-02-10 US disclosed
EP-2275404-A1 HOMOCYSTEINE SYNTHASE INHIBITOR Mitsubishi Tanabe Pharma Corporation (JP) 2011-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196824-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION FABP7, TIMP3, MMP11 ALDH1A1 180/4885NPC1 450/4885RAB9A 1221/4885
US-20110034440-A1 HOMOCYSTEINE SYNTHASE INHIBITOR BHMT, CBS, BHMT2 ALDH1A1 600/4885NPC1 1230/4885RAB9A 3994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.